Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value

References

• Greaves M. Aetiology of acute leukaemia. Lancet. 1997;349:344–349.
   PubMed Web of Science ®Google Scholar
• Pui C, Campana D, Kaste S, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730–2741.
   PubMed Web of Science ®Google Scholar
• Schultz K, Pullen D, Sather H, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the pediatric oncology group (POG) and children’s cancer group (CCG). Blood. 2007;109(3):926.
   PubMed Web of Science ®Google Scholar
• Gatta G, Botta L, Clavel J, EUROCARE Working Group, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):35–47.
   PubMed Web of Science ®Google Scholar
• Borowitz M, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children’s oncology group study. Blood. 2008;111(12):5477–5485.
   PubMed Web of Science ®Google Scholar
• Berry D, Zhou S, Radich J, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;13(7):e170580.
   Google Scholar
• Borowitz M, Wood B, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from children’s oncology group study AALL0232. Blood. 2015;126(8):964–971.
   PubMed Web of Science ®Google Scholar
• Cavaillon J. Pro- versus anti-inflammatory cytokines : myth or reality? Cell Mol Biol. 2001;47(4):695–702.
   PubMed Web of Science ®Google Scholar
• Komada Y, Sakurai M. Cytokines and cytokine receptors in acute lymphoblastic leukemia expressing myeloid markers-role in growth regulation. Leuk Lymphoma. 1994;15(5–6):411–418.
   PubMed Web of Science ®Google Scholar
• Shin GS, Lee BH, Lim J, et al. Monokine levels in cancer and infection. Ann Clin Lab Sci. 2003;33(2):149–155.
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene. 2007;26(47):6738–6749.
   PubMed Web of Science ®Google Scholar
• Sachs L. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci USA. 1996;93:4742–4749.
   PubMed Web of Science ®Google Scholar
• Moqattash S, Lutton J. Leukemia cells and the cytokine network. Proc Soc Exp Biol Med. 1998;219:8–27.
   PubMed Web of Science ®Google Scholar
• Foell D, Kucharzik T, Domschke W, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52(6):847–853.
   PubMed Web of Science ®Google Scholar
• Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like recepter 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:883–891.
   PubMed Web of Science ®Google Scholar
• Kessel C, Fuehner S, Brockmeyer S, et al. Calcium and zinc tune autoinflammatory toll-like receptor 4 signaling by S100A12. J Allergy Clin Immunol. 2018;142(4):1370–1373.e8.
   PubMed Web of Science ®Google Scholar
• Foell D, Wittkowski H, Varga G, et al. Proinflammatory S100A12 can activate human monocytes via toll-like receptor 4. Am J Respir Crit Care Med. 2013;187(12):1324–1334.
   PubMed Web of Science ®Google Scholar
• Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol. 2013;147(3):229–241.
   PubMed Web of Science ®Google Scholar
• Wittkowski H, Frosch M, Wulffraat N, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58(12):3924–3931.
   PubMed Web of Science ®Google Scholar
• Xia Y, Cui P, Yang J, et al. Extremely elevated IL-18 levels may help distinguish systemic-onset juvenile idiopathic arthritis from other febrile diseases. Brazilian J Med Biol Res. 2017;50(2):1–7.
   Web of Science ®Google Scholar
• Horacek JM, Kupsa T, Zak P, et al. Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia. Biomed Pap. 2015;159(2):299–301.
   PubMed Web of Science ®Google Scholar
• Park HH, Kim M, Lee EJ, et al. Intracellular IL-4, IL-10, and IFN-γ levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci. 2006;36(1):7–15.
   PubMed Web of Science ®Google Scholar
• Aguayo A, Estey E, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94(11):3717–3721.
   PubMed Web of Science ®Google Scholar
• Nicolas E, Ramus C, Berthier S, et al. Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients. Leukemia. 2011;25(1):57–65.
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating MJ, Lerner S, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97(1):256–263.
   PubMed Web of Science ®Google Scholar
• Wu S, Geßner RV, Seeger K, et al. Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence. Cancer. 2005;103(5):1054–1063.
   PubMed Web of Science ®Google Scholar
• Brix N, Glerup M, Herlin T, et al. M-ficolin: a valuable biomarker to identify leukemia from juvenile idiopathic arthritis. Arch Dis Child. 2021;371–376.
   PubMed Web of Science ®Google Scholar
• Cleveland W. Robust locally-weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829.
   Web of Science ®Google Scholar
• Van Calster B, McLernon DJ, Bossuyt P, et al. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):1–7.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–1931.
   PubMed Web of Science ®Google Scholar
• Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50(12):3762–3771.
   PubMedGoogle Scholar
• Bruserud O, Akselen PE, Bergheim J, et al. Serum concentrations of E-selectin. P-selectin. ICAM- 1 and interleukin 6 in acute leukemia patients with chemotherapy- induced leucopenia and bacterial infections. Br J Haematol. 1995;91(2):394–402.
   PubMed Web of Science ®Google Scholar
• Bruserud 0, Bergheim J, Nesthus I, et al. Serum concentrations of tumour necrosis factor- during chemotherapy-induced leukopenia in patients with acute leukemia and bacterial-infections. Leuk Res. 1994;18:415–421.
   PubMed Web of Science ®Google Scholar
• Potapnev MP, Petyovka NV, Migal NV, et al. Plasma level of tumor necrosis factor-alpha (TNF-α) correlates with leukocytosis and biological features of leukemic cells, but not treatment response of children with acute lymphoblastic leukemia. Leuk Lymphoma. 2003;44(6):1077–1079.
   PubMedGoogle Scholar
• Pieters R, de Groot-Kruseman H, Van der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group. J Clin Oncol. 2016;34(22):2591–2601.
   PubMed Web of Science ®Google Scholar
• Yeoh A, Ariffin H, Chai E, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol. 2012;30(19):2384–2392.
   PubMed Web of Science ®Google Scholar